Real-World Recurrence Rates and Economic Burden in Patients with Resected Early-Stage Melanoma
Dermatology and Therapy - 2020
Tóm tắt
Real-world data on recurrence and economic burden in patients with resected early-stage melanoma are limited. The objective of this study was to assess real-world recurrence rates, risk factors for recurrence, and costs of recurrence in patients with resected stage IIB, IIC, or IIIA melanoma in the USA. This retrospective analysis included patients with resected stage IIB, IIC, or IIIA melanoma (American Joint Committee on Cancer staging manual, seventh edition) in the Surveillance, Epidemiology, and End Results (SEER) program–Medicare database of the National Cancer Institute. Recurrence rates and healthcare costs (2018 USD) after recurrence were assessed. Two-year recurrence rates for stages IIB, IIC, and IIIA melanoma were 29, 44, and 46%, respectively. In patients with stage IIB or IIC disease, the odds of recurrence were significantly higher in those aged > 75 years [odds ratio (OR) 1.853, 95% confidence interval (CI) 1.416, 2.425], with ulceration (OR 1.771; 95% CI 1.293, 2.425), or with a higher Charlson Comorbidity Index (OR 1.244; 95% CI 1.129, 1.372); however, the odds of recurrence were significantly lower in those with T3 staging (OR 0.522; 95% CI 0.393, 0.695). In those with stage IIIA melanoma, superficial spreading was associated with significantly lower odds of recurrence (OR 0.178; 95% CI 0.053, 0.601). Following recurrence, mean healthcare costs at 1 year were $31,870 for patients with stage IIB or IIC melanoma and $29,224 for those with stage IIIA melanoma. The SEER data show that a substantial proportion of adults with early-stage melanoma experience a recurrence within 2 years following resection, resulting in a significant economic burden to the US healthcare system. Dermatologists can distinguish patients with resected early-stage melanoma who are at a high risk for recurrence and consider referrals to medical oncologists for approved adjuvant therapy or enrollment in clinical trials after surgical resection to reduce the recurrence of melanoma. Melanoma is the sixth most common type of cancer in the USA. In the past several years, the US Food and Drug Administration has approved several novel therapies for patients with high-risk melanoma following surgery. However, these therapies are not approved for the treatment of patients with earlier-stage or intermediate-risk melanoma. In these patients, treatment choices include enrollment in clinical trials or observation. We have assessed recurrence rates, risk factors for recurrence, and costs of recurrence in patients with early-stage melanoma. This analysis included patients with resected early-stage melanoma in the US Surveillance, Epidemiology, and End Results (SEER) program–Medicare database. The results show that a substantial proportion of adults with early-stage melanoma experienced a recurrence within 2 years after surgical removal of their tumor, resulting in a significant economic burden to the healthcare system. Dermatologists can use information in the published literature to distinguish patients with resected early-stage melanoma who are at a high risk for recurrence and consider referrals to medical oncologists for approved therapy or enrollment in clinical trials after surgery to reduce recurrence and substantial economic consequences.
Từ khóa
Tài liệu tham khảo
US Cancer Statistics Working Group. US Cancer Statistics Data Visualizations Tool, based on November 2018 submission data (1999–2016): US Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute. 2019. https://gis.cdc.gov/Cancer/USCS/DataViz.html. Accessed November 2019.
National Comprehensive Cancer Network®. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®): Cutaneous Melanoma Version 1.2020. https://www.nccn.org/professionals/physician_gls/pdf/cutaneous_melanoma.pdf. Accessed Jan 2020.
Weber J, Mandala M, Del Vecchio M, et al. Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma. N Engl J Med. 2017;377(19):1824–35.
Long GV, Hauschild A, Santinami M, et al. Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma. N Engl J Med. 2017;377(19):1813–23.
Eggermont AMM, Blank CU, Mandala M, et al. Adjuvant pembrolizumab versus placebo in resected stage III melanoma. N Engl J Med. 2018;378(19):1789–801.
Balch CM, Gershenwald JE, Soong SJ, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol. 2009;27(36):6199–206.
Gershenwald JE, Scolyer RA, Hess KR, et al. Melanoma staging: evidence-based changes in the American Joint Committee on Cancer Eighth Edition Cancer Staging Manual. CA Cancer J Clin. 2017;67:472–92.
Bajaj S, Donnelly D, Call M, et al. Melanoma prognosis accuracy of the American Joint Committee on Cancer Staging Manual Eighth Edition. J Natl Cancer Inst. 2020. https://doi.org/10.1093/jnci/djaa008.
Bleicher J, Swords DS, Bowles TL, Hyngstrom JR. Patterns of recurrence in stage II cutaneous melanoma. Ann Surg Oncol. 2019;26:S160 (Abstract P273).
Leiter U, Buettner PG, Eigentler TK, et al. Hazard rates for recurrent and secondary cutaneous melanoma: an analysis of 33,384 patients in the German Central Malignant Melanoma Registry. J Am Acad Dermatol. 2012;66:37–45.
Melanoma Research Alliance. Interferon (Intron® A or Sylatron™). https://www.curemelanoma.org/patient-eng/melanoma-treatment/adjuvant-therapy/interferon-intron-a-or-sylatron/. 2016. Accessed December 2019.
Kirkwood JM, Strawderman MH, Ernstoff MS, et al. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol. 1996;14(1):7–17.
Kirkwood JM, Ibrahim JG, Sondak VK, et al. High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190. J Clin Oncol. 2000;18(12):2444–58.
Agarwala SS, Lee SJ, Flaherty LE, et al. Randomized phase III trial of high-dose interferon alfa-2b (HDI) for 4 weeks induction only in patients with intermediate- and high-risk melanoma (Intergroup trial E 1697). J Clin Oncol. 2011;29(15 Suppl):8505.
National Cancer Institute, Division of Cancer Control and Population Sciences. Surveillance, Epidemiology, and End Results (SEER). 2018. https://seer.cancer.gov/about/factsheets/SEER_Overview.pdf. Accessed Nov 2019.
Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care. 2005;43(11):1130–9.
Warren JL, Mariotto A, Melbert D, et al. Sensitivity of Medicare claims to identify cancer recurrence in elderly colorectal and breast cancer patients. Med Care. 2016;54(8):e47–54.
US Department of Health and Human Services. Health Resources and Services Administration (HRSA). Consumer price index for medical care. 2018. https://www.hrsa.gov/get-health-care/affordable/hill-burton/cpi.html. Accessed March 2020.
Romano E, Scordo M, Dusza SW, et al. Site and timing of first relapse in stage III melanoma patients: implications for follow-up guidelines. J Clin Oncol. 2010;28(18):3042–7.
Tarhini A, Ghate SR, Ionescu-Ittu R, et al. Postsurgical treatment landscape and economic burden of locoregional and distant recurrence in patients with operable nonmetastatic melanoma. Melanoma Res. 2018;28(6):618–28.
Gassenmaier M, Keim U, Leiter U, et al. Age as key factor for pattern, timing and extent of distant metastasis in patients with cutaneous melanoma: a study of the German Central Malignant Melanoma Registry. J Am Acad Dermatol. 2019;80:1299–307.
Seidler AM, Pennie ML, Veledar E, et al. Economic burden of melanoma in the elderly population: population-based analysis of the Surveillance, Epidemiology, and End Results (SEER)–Medicare data. Arch Dermatol. 2010;146(3):249–56.
Davis KL, Mitra D, Kotapati S, et al. Direct economic burden of high-risk and metastatic melanoma in the elderly: evidence from the SEER–Medicare linked database. Appl Health Econ Health Policy. 2009;7(1):31–41.
Buja A, Sartor G, Scioni M, et al. Estimation of direct melanoma-related costs by disease stage and by phase of diagnosis and treatment according to clinical guidelines. Acta Derm Venereol. 2018;98(2):218–24.
Sosman JA, Moon J, Tuthill RJ, et al. A phase 2 trial of complete resection for stage IV melanoma: results of Southwest Oncology Group Clinical Trial S9430. Cancer. 2011;117(20):4740–6.
Howard JH, Thompson JF, Mozzillo N, et al. Metastasectomy for distant metastatic melanoma: analysis of data from the first Multicenter Selective Lymphadenectomy Trial (MSLT-I). Ann Surg Oncol. 2012;19(8):2547–55.